SCHEMBL213444

SCHEMBL213444

COc1ccc(CNc2c(N)c(Cl)nc3ccccc23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.62
NCF1 P14598 1/20 0.60
EGFR P00533 2/20 0.56
ACP1 P24666 3/20 0.54
POLB P06746 4/20 0.52
NR2F2 P24468 1/20 0.51
RAD52 P43351 2/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
SLC2A1 P11166 1/20 0.49
KDM1A O60341 1/20 0.48
GFER P55789 1/20 0.48
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137771 0.90 APP (0.62) APPNCF1EGFRACP1POLB
SCHEMBL13968056 0.87 KMT2A (0.66) APPPOLBRAD52KMT2ALMNA
SCHEMBL28802725 0.85 POLB (0.47) APPNCF1EGFRACP1POLB
SCHEMBL8121604 0.82 KMT2A (0.55) APPPOLBRAD52KMT2AMAPT
SCHEMBL211489 0.81 POLB (0.51) APPPOLBRAD52KMT2ACYP1A2
SCHEMBL27213620 0.81 APP (0.42) APPNCF1EGFRPOLBRAD52
SCHEMBL210947 0.81 EGFR (0.78) APPNCF1EGFRACP1POLB
SCHEMBL21013099 0.80 KMT2A (0.50) APPPOLBRAD52KMT2A
SCHEMBL29381485 0.80 KMT2A (0.50) APPPOLBRAD52KMT2A
SCHEMBL28872741 0.79 POLB (0.46) APPPOLBRAD52KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 WO disclosed
EP-1948173-B1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2013-07-17 EP disclosed
US-8377957-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES COMPANY 2012-03-22 US disclosed
US-8088790-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS PFIZER INC. 2009-09-03 US disclosed
EP-1948173-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-07-30 EP disclosed
WO-2007056112-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 APP 4434/4885NCF1 732/4885EGFR 3299/4885
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 APP 4434/4885NCF1 732/4885EGFR 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.